BioXcel Therapeutics (BTAI) Receivables - Other (2018 - 2019)
BioXcel Therapeutics (BTAI) posted quarterly Receivables - Other of $46000.0 for Q2 2019, down 34.29% year-over-year from $70000.0 in Q2 2018, and down 60.0% quarter-over-quarter from $115000.0 in Q4 2018.
BioXcel Therapeutics (BTAI) Receivables - Other (2018 - 2019) Analysis & Trends
BioXcel Therapeutics' Receivables - Other history runs 2 years deep, the most recent figure standing at $46000.0 for Q2 2019.
- In Q2 2019, Receivables - Other fell 34.29% year-over-year to $46000.0; the TTM figure through Jun 2019 stood at $46000.0 (down 34.29% YoY), while the FY2018 annual figure was $115000.0, changed N/A from the prior year.
- Receivables - Other for Q2 2019 stood at $46000.0, down from $115000.0 in the prior quarter.
- The five-year high for Receivables - Other was $115000.0 in Q4 2018, with the low at $44000.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | BioXcel Therapeutics | 24.29 Mn | 24.29 Mn | 160,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 46,000.00 |
| Jun 30, 2019 | 46,000.00 |
| Dec 31, 2018 | 115,000.00 |
| Dec 31, 2018 | 115,000.00 |
| Sep 30, 2018 | 49,000.00 |
| Sep 30, 2018 | 49,000.00 |
| Jun 30, 2018 | 70,000.00 |
| Jun 30, 2018 | 70,000.00 |
| Mar 31, 2018 | 44,000.00 |
| Mar 31, 2018 | 44,000.00 |